Developing guidelines for biotechnology drug use: Experience with antithrombin III

D. R. Romac, P. Poole, John T Owings, K. Mahackian, G. Foulke, R. S. Tharratt, Timothy E Albertson

Research output: Contribution to journalArticle

Abstract

Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.

Original languageEnglish (US)
Pages (from-to)520-531
Number of pages12
JournalFormulary
Volume30
Issue number9
StatePublished - 1995

Fingerprint

Antithrombin III
Biotechnology
Guidelines
Pharmaceutical Preparations
Formularies
Drug Costs

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Romac, D. R., Poole, P., Owings, J. T., Mahackian, K., Foulke, G., Tharratt, R. S., & Albertson, T. E. (1995). Developing guidelines for biotechnology drug use: Experience with antithrombin III. Formulary, 30(9), 520-531.

Developing guidelines for biotechnology drug use : Experience with antithrombin III. / Romac, D. R.; Poole, P.; Owings, John T; Mahackian, K.; Foulke, G.; Tharratt, R. S.; Albertson, Timothy E.

In: Formulary, Vol. 30, No. 9, 1995, p. 520-531.

Research output: Contribution to journalArticle

Romac, DR, Poole, P, Owings, JT, Mahackian, K, Foulke, G, Tharratt, RS & Albertson, TE 1995, 'Developing guidelines for biotechnology drug use: Experience with antithrombin III', Formulary, vol. 30, no. 9, pp. 520-531.
Romac DR, Poole P, Owings JT, Mahackian K, Foulke G, Tharratt RS et al. Developing guidelines for biotechnology drug use: Experience with antithrombin III. Formulary. 1995;30(9):520-531.
Romac, D. R. ; Poole, P. ; Owings, John T ; Mahackian, K. ; Foulke, G. ; Tharratt, R. S. ; Albertson, Timothy E. / Developing guidelines for biotechnology drug use : Experience with antithrombin III. In: Formulary. 1995 ; Vol. 30, No. 9. pp. 520-531.
@article{8b7cfc59fb2247c5b9dbfd6188b2d42d,
title = "Developing guidelines for biotechnology drug use: Experience with antithrombin III",
abstract = "Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.",
author = "Romac, {D. R.} and P. Poole and Owings, {John T} and K. Mahackian and G. Foulke and Tharratt, {R. S.} and Albertson, {Timothy E}",
year = "1995",
language = "English (US)",
volume = "30",
pages = "520--531",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "9",

}

TY - JOUR

T1 - Developing guidelines for biotechnology drug use

T2 - Experience with antithrombin III

AU - Romac, D. R.

AU - Poole, P.

AU - Owings, John T

AU - Mahackian, K.

AU - Foulke, G.

AU - Tharratt, R. S.

AU - Albertson, Timothy E

PY - 1995

Y1 - 1995

N2 - Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.

AB - Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.

UR - http://www.scopus.com/inward/record.url?scp=0029147149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029147149&partnerID=8YFLogxK

M3 - Article

C2 - 10151737

AN - SCOPUS:0029147149

VL - 30

SP - 520

EP - 531

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 9

ER -